# Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML

> **NCT00430443** · PHASE1 · TERMINATED · sponsor: **Callisto Pharmaceuticals** · enrollment: 3 (actual)

## Conditions studied

- Acute Lymphocytic Leukemia
- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Liposomal Annamycin

## Key facts

- **NCT ID:** NCT00430443
- **Lead sponsor:** Callisto Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-02
- **Primary completion:** —
- **Final completion:** 2009-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Participants are no longer being examined or treated.
- **Last updated:** 2011-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00430443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00430443, "Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00430443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*